[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408853":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":33,"locations":43,"responsibleParty":60,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":32,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":32,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of CD19\u002FBCMA Targeted CAR T-cells and dasatinib","EXPERIMENTAL","Dose levels of CAR-T cells are based on clinical trials of similar foreign products. Meanwhile, dasatinib would be combined as the following regimens: 1) Dasatinib preconditioning CAR-T cells during the manufacturing; 2) Dasatinib for the intervention of cytokine release storm after CAR-T cell infusion; 3) Dasatinib for the intervention of neurotoxicities after CAR-T cell infusion; 4) Dasatinib for the phase of CAR-T cell decreasing.",[13],"Drug: CD19\u002FBCMA Targeted CAR T-cells and dasatinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Administration of CD19\u002FBCMA Targeted CAR T-cells","Dose levels of CAR-T cells are based on clinical trials of similar foreign products.",[18],"Drug: CD19\u002FBCMA Targeted CAR T-cells",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","CD19\u002FBCMA Targeted CAR T-cells and dasatinib","Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.",[9],[9],{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"CD19\u002FBCMA Targeted CAR T-cells","Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.",[15],[31],"CD19\u002FBCMA Targeted CAR T-cells infusion",null,[34,39],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"He Huang, PhD","CONTACT","86-13605714822","hehuangyu@126.com",{"name":40,"role":36,"phone":41,"phoneExt":32,"email":42},"Yongxian Hu, PhD","86-15957162012","huyongxian2000@aliyun.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"The First Hospital of Zhejiang Medical Colleage Zhejiang University","RECRUITING","Hangzhou","Zhejiang","310003","China","CN",{"type":53,"coordinates":54},"Point",[55,56],120.16142,30.29365,{"lat":56,"lon":55},[59],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","He Huang","Clinical Professor",[65],{"name":66,"class":67},"Yake Biotechnology Ltd.","INDUSTRY","100408853","early-phase-1-car-t-cells-combined-with-dasatinib-for-patients-with-relapsed-andor-refractory-b-cell-hematological-malignancies-100408853",false,"NCT04603872","CAR-T Cells Combined With Dasatinib for Patients With Relapsed and\u002For Refractory B-cell Hematological Malignancies","Clinical Trial for the Safety and Efficacy of CD19\u002FBCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and\u002For Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of CD19+ ALL, CD19+ NHL, or BCMA+ MM per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (2020.v2);\n2. Relapsed or refractory B cell hematological malignancies (meeting one of the following conditions):\n\n   1. CR not achieved after standardized chemotherapy;\n   2. CR achieved following the first induction, but CR duration is less than 12 months;\n   3. Ineffectively after first or multiple remedial treatments;\n   4. 2 or more relapses;\n   5. Relapse after hematopoietic stem cell transplantation;\n   6. Extramedullary leisions which were ineffective to radiotherapy or chemotherapy;\n3. Total bilirubin ≤ 51 umol\u002FL, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol\u002FL;\n4. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;\n5. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;\n6. Estimated survival time ≥ 12 weeks;\n7. ECOG performance status 0 to 2;\n8. Women of childbearing age had negative pregnancy test during screening period and before administration, and agreed to take effective contraceptive measures at least one year after infusion.\n9. Patients volunteer to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\nSubjects with any of the following exclusion criteria were not eligible for this trial:\n\n1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;\n2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n3. Pregnant (or lactating) women;\n4. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);\n5. Active infection of hepatitis B virus or hepatitis C virus;\n6. Concurrent therapy with systemic steroids within 2 weeks prior toscreening, except for the patients recently or currently receiving in haledsteroids;\n7. Previously treated with any CAR-T cell product or other genetically-modified T cell therapies;\n8. Creatinine \\>2.5mg\u002Fdl, or ALT \u002F AST \\> 3 times of normal amounts, or bilirubin \\>2.0 mg\u002Fdl;\n9. Other uncontrolled diseases that were not suitable for this trial;\n10. Patients with HIV infection;\n11. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.","ALL","18 Years","70 Years",{"count":79,"type":80},120,"ESTIMATED","INTERVENTIONAL",[83],"EARLY_PHASE1","A Study of CD19\u002FBCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and\u002For Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.",[86,87,88,89,90,91],"Multiple Myeloma in Relapse","Multiple Myeloma, Refractory","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphocytic Leukaemia Refractory","Non-Hodgkin's Lymphoma, Relapsed","Non-Hodgkin's Lymphoma Refractory",[93,94,95,96,97],"Acute Lymphoblastic Leukemia","Non-Hodgkin's Lymphoma","Multiple Myeloma","CAR T-cell therapy","Dasatinib","2020-10-27",{"date":100,"type":101},"2020-10-28","ACTUAL",{"date":103,"type":80},"2020-11-01",{"date":105,"type":80},"2026-11-01",{"name":5,"class":6},1]